medigraphic.com

2022, Number 2

<< Back Next >>

Rev Cuba Endoc 2022; 33 (2)

Hormonal diagnosis of polycystic ovary syndrome

Ovies CG, Monteagudo PG, Gómez AM, Cabrera GM

Language: Spanish
References: 42
Page:
PDF size: 207.43 Kb.


ABSTRACT

Introduction: Polycystic ovary syndrome is the most common endocrine disorder in women during the reproductive stage. Several consensuses have been made in order to define its diagnostic criteria and hyperandrogenism has always been present, either clinical or mood related.
Objective: To describe the aspects related to hormonal diagnosis in polycystic ovary syndrome.
Methods: A literature review was performed on aspects related to the hormonal diagnosis of polycystic ovary syndrome. Original articles in English were obtained from Pubmed, Google Scholar, EMBASE and MEDLINE databases. Priority was given to the MESH BROWSER term polycystic ovary syndrome.
Results: The hormonal diagnosis of polycystic ovary syndrome should demonstrate hyperandrogenism biochemically, whenever possible, although if there is clinical evidence based on the diagnostic criteria themselves it is not mandatory. The most useful laboratory method appears to be the determination of free testosterone or instead that of the free androgen index, followed by total testosterone. Other androgen determinations are of less value as first line.


REFERENCES

  1. American College of Obstetricians and Gynecologists. Practice Bulletin 41 on polycystic ovary syndrome can be found at Obstet Gynecol. ACOG. 1990 [acceso: 26/08/2021];100(1):389-91. Disponible en: https://journals.lww.com/greenjournal/Fulltext/2002/12000/ACOG_Practice_Bulletin_No__41__Polycystic_Ovary.42.aspx1.

  2. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group Revised. Consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Hum Reprod. 2004 [acceso: 26/08/2021];19(1):41-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/14688154/2.

  3. Azziz R, Carmina E, Dewally D. Position Statement: Criteria for defining Polycystic Ovary Syndrome as a predominantly hyperandrogenyc syndrome: An Androgen Excess Society Guideline. J Clin Endocrinol Metab. 2006 [acceso: 26/08/2021];91(11):4237-45. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16940456/3.

  4. Dumesic DA, Ober?eld SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scienti?c Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Rev Endocr. 2015 [acceso: 26/08/2021];36(5):487-525. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591526/4.

  5. Fauser BC, Tarlatzis BC, Rebar RW. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012 [acceso: 26/08/2021];97(1):28-38. Disponible en: https://pubmed.ncbi.nlm.nih.gov/22153789/5.

  6. Boots l, Potter S, Potter H, Azziz R. Measurement of total serum testosterone levels using commercially available kits: high degree of between-kit variability. Fertil Steril. 1998 [acceso: 26/08/2021];69(2):286-92. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9496343/6.

  7. Moal V, Mathieu E, Reynier P, Malthièry Y, Gallois Y. Low serum testosterone assayed by liquid chromatography-tandem mass spectrometry. Comparison with five immunoassay techniques. Clin Chim Acta. 2007 [acceso: 26/08/2021];386(1-2):12-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17706625/7.

  8. Ayala C, Steinberger E, Smith KD, Rodríguez-Rigau lJ, Petak SM. Serum testyosterone levels and reference ranges in reproductive-age woman. Edocr Pract. 1999 [acceso: 26/08/2021];5(6):322-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/15251653/8.

  9. Taieb J, Mathian B, Millot F, Patricot M, Mathieu E, Queyrel N, et al. Testosterone measurement by 10 immunoassays and isotope-dilution gas chromatography-mass spectrometry in sera from 116 men, women and children. Clin Chem. 2003 [acceso: 26/08/2021];49(8):1381-95. Disponible en: http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.540.5480&rep=rep1&type=pdf9.

  10. Dacunda M, D'Amico M, De la Vega L, Gómez E, Jaeggi E, Navia MR, et al. Dificultades técnicas en la medición de testosterona. Rev Arg Endocrinol & Metabol. 2016 [acceso: 26/08/2021];53(3):114-8. Disponible en: https://www.researchgate.net/publication/305624665_Dificultades_tecnicas_en_el_dosaje_de_testosterona10.

  11. Fox R, Corrigan E, Thomas PA. The diagnosis of polycystic ovaries in women with oligo-amenorrhoea: predictive power of endocrine tests. Clin Endocrinol (Oxf). 1991 [acceso: 26/08/2021];34(2):127-31. Disponible en: https://pubmed.ncbi.nlm.nih.gov/2022063/11.

  12. Rosner W, Auchus RJ, Azzis R, Sluss PM. "Position statement: utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society Position statement." J Clin Endocrinol Metab. 2002 [acceso: 26/08/2021];92(2):405-13. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17090633/12.

  13. Teede H, Misso M, Costello A, Laven J, Moran L, Piltonen T, et al. The International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol. 2018 [acceso: 26/08/2021];33(9):1602-18. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30033227/13.

  14. Morán C, Hernández M, Cravioto M, Porias HL, Malacara JM, Bermúdez JA. Síndrome de Ovario Poliquístico. Posición De La Sociedad Mexicana de Nutrición y Endocrinología. Rev Endocrinol Nutr. 2006 [acceso: 26/08/2021];14(1):7-12. Disponible en: https://www.medigraphic.com/pdfs/endoc/er-2006/er061b.pdf14.

  15. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W, et al. Position statement: Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. J Clin Endocrinol Metab. 2006 [acceso: 26/08/2021];91(11):4237-45. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16940456/15.

  16. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale H, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task forcé report. Fertil Steril. 2009 [acceso: 26/08/2021];91(2):456-88. Disponible en: https://pubmed.ncbi.nlm.nih.gov/18950759/16.

  17. Ternt M, Gordon C. Diagnosis and Management of Polycystic Ovary Syndrome in Adolescents. Pediatrics. 2020 [acceso: 26/08/2021];145(Suppl 2): 210-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32358213/17.

  18. Huang A, Brennan K, Azziz R. Prevalence of hyperandrogenemia in the poly-cystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria. Fertil Steril. 2010 [acceso: 26/08/2021];93(6):1938-41. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859983/18.

  19. Nisenblat V, Norman R. Androgens and polycystic ovary syndrome. Curr Opin Endocrinol Diabetes Obes. 2009 [acceso: 26/08/2021];16(3):224-31. Disponible en: https://pubmed.ncbi.nlm.nih.gov/19390322/19.

  20. O'Reilly M, Taylor A, Crabtree N. Hyperandrogenemia predicts meta-bolic phenotype in polycystic ovary syndrome: the utility of serum andros-tenedione. J Clin Endocrinol Metab. 2014 [acceso: 26/08/2021];99(3):1027-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24423344/20.

  21. Azziz R. Polycystic ovary syndrome. Obstet Gynecol. 2018 [acceso: 26/08/2021];132(2):321-36. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29995717/21.

  22. Wang C, Catlin D, Demers L, Starcevic B, Swerdloff R. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab. 2004 [acceso: 26/08/2021];89(2):534-43. Disponible en: https://pubmed.ncbi.nlm.nih.gov/14764758/22.

  23. Sanabria C, Díaz JA. Valoración de niveles de testosterona mediante diferentes métodos analíticos en varones sanos. Endocrinol Diabetes Nutric. 2010 [acceso: 26/08/2021];89(2):301-5. Disponible en: https://medes.com/publication/6066323.

  24. Taylor A, McCourt B, Martin K, Anderson E, Adams J, Schoebfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with PCOS. J Clin Endocrinol Metab. 1997 [acceso: 26/08/2021];2(7):2248-56. Disponible en: https://pubmed.ncbi.nlm.nih.gov/9215302/24.

  25. Waldstreicher J, Santoro NF, Hall HJ, Filicori M, Crowley WF. Hyperfunction of the hypothalamic-pituitary axis in women with polycystic ovarian disease: indirect evidence of partial gonadotroph desensitization. J Clin Endocrinol Metab. 1988 [acceso: 26/08/2021];66(1):165-72. Disponible en: https://pubmed.ncbi.nlm.nih.gov/2961784/25.

  26. Fauser B, Pache T, Lamberts S, Hop W, de Jong F, Dahl K. Serum bioactive and immunoreactive LH and FSH levels in women with cycle abnormalities, with or without PCOD. J Clin Endocrinol Metab. 1991 [acceso: 26/08/2021];73(4):811-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/1909705/26.

  27. Tam M. Exploration of the role of anti-Mullerian hormone and LH/FSH ratio in diagnosis of polycystic ovary syndrome. Clin Endocrinol. 2019 [acceso: 26/08/2021];90(4):579-85. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30636332/27.

  28. Bhide P, Shah A, Gudi A, Homburg R. The role of anti-Müllerian hormone as a predictor of ovarian function. Obstet Gynecol. 2012 [acceso: 26/08/2021];14(3):161-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23352101/28.

  29. Wiweko B, Maidarti M, Priangga MD, Shafira N, Fernando D, Sumapraja K, et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J Assist Reprod Genet. 2014 [acceso: 26/08/2021];31(10):1311-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25119192/29.

  30. Sahmay S, Aydin Y, Oncul M, Senturk LM. Diagnosis of polycystic ovary syndrome: AMH in combination with clinical symptoms. J Assist Reprod Genet. 2014 [acceso: 26/08/2021];31(2):213-20. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24343036/30.

  31. Cheviakoff S, Carmona S, Lahsen R. Estudios de variables clínicas y metabólicas en mujeres con hiperandrogenismo clínico. Rev Chil Obstet Ginecol. 2004 [acceso: 26/08/2021];69(1):39-43. Disponible en: https://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0717-7526200400010000831.

  32. Gutiérrez P, Jefferson L, Rechkemmer A, Contreras H. Poliquístosis Ovárica: Hallazgos Clínicos y Hormonales. Rev Per Ginecol Obstetr. 2001 [acceso: 26/08/2021];47(1):16-21. Disponible en: http://www.spog.org.pe/web/revista/index.php/RPGO/article/view/4632.

  33. Acosta A, Monteagudo G, Menocal A. Patrón hormonal de mujeres con diagnóstico clínico y ecográfico del síndrome de ovarios poliquistios. Rev Cubana Endocrinol. 2004 [acceso: 26/08/2021];15(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-2953200400020000333.

  34. Carvajal R, Herrera C, Porcile A. Espectro fenotípico del síndrome de ovario Poliquístico. Rev Chil Obstet Ginecol. 2010 [acceso: 26/08/2021];75(2):124-32. Disponible en: https://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0717-7526201000020000934.

  35. Vázquez JC, Calero JL, Carías JP, Monteagudo G. Correspondencia clínica, hormonal y ecográfica en el diagnóstico del síndrome de ovario poliquístico. Rev Cub Endocrinol. 2016 [acceso: 26/08/2021];27(1):4-17. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-2953201600010000235.

  36. Wiweko B, Maidarti M, Priangga MD, Shafira N, Darrell F, Sumapraja K, et al. J Assist Reprod Genet. 2014 [acceso: 26/08/2021];31(10):1311-6. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4171421/36.

  37. Ahmed N, Batarfi A, Bajouh O, Bakhashah S. Serum Anti-Müllerian Hormone in the Diagnosis of Polycystic Ovary Syndrome in Association with Clinical Symptoms Diagnostics. Diagnostics (Basel). 2019 [acceso: 26/08/2021];9(4):136. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31581541/37.

  38. Wongwananuruk T, Panichyawat N, Indhavivadhana S, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, et al. Accuracy of anti-Müllerian hormone and total follicles count to diagnose polycystic ovary syndrome in reproductive women. Taiwan J Obstet Gynecol. 2018 [acceso: 26/08/2021];57(4):499-506. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30122568/38.

  39. Matsuzaki T, Munkhzaya M, Iwasa T, Tungalagsuvd A, Yano K, Mayila Y, et al. Relationship between serum anti-Mullerian hormone and clinical parameters in polycystic ovary syndrome. Endocr J. 2017 [acceso: 26/08/2021];64(5):531-41. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28381699/39.

  40. Rodríguez A, Sanz M, Echeverría M. Hiperplasia suprarrenal congénita por déficit de 21-hidroxilasa. Pediatr Integral. 2015 [acceso: 26/08/2021];XIX:488-97. Disponible en: https://www.pediatriaintegral.es/publicacion-2015-09/hiperplasia-suprarrenal-congenita-por-deficit-de-21-hidroxilasa/40.

  41. Guzmán J, Robles F, Rivera O, Ramírez F, Sepúlveda A, Sepúlveda J. Revisión de los criterios diagnósticos para el síndrome de ovario poliquístico. J MED UIS. 2020 [acceso: 26/08/2021];33(3):21-8. Disponible en: https://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/1182141.

  42. Williams T, Mortada R, Poter S. Diagnosis and Treatment of Polycystic Ovary Syndrome. Am Fam Physicican. 2016 [acceso: 26/08/2021];94(2):116-3. Disponible en: https://www.aafp.org/afp/2016/0715/p106.html42.




2020     |     www.medigraphic.com